This webcast features: Andrew Lees, PhD, Founder and Scientific Director, Fina Biosolutions, LLC Tetanus toxoid (TT) is frequently used as a carrier protein for conjugate vaccines. TT contains strong T cell epitopes. They are toxoided protein and are not a uniform product because of specific toxoiding and purification processes. TT tends to aggregate with age and is not affordable to produce in quantities for research and early clinical work. TT heavy chain fragment C (rTTHc) is the C terminal fragment…
Monday, August 31, 2020 Daily Archives
New technologies can solve downstream bottlenecks says expert
Biopharma needs to embrace new downstream processing technologies to overcome its manufacturing issues, according to an expert. Industry is reluctant to adopt new downstream technologies because firms prefers systems with which staff are familiar, said Alois Jungbauer from the Austrian Centre of Industrial Biotechnology at the University of Natural Resources and Life Sciences. He began by asking delegates at the BPI Europe virtual conference in July: “Why is chromatography so popular? “It’s the high selectivity. It’s the high resolution. We…